This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Intranasal triamcinolone versus intranasal beclomethasone for acute and chronic sinus inflammation: a review of comparative clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013
Findings from the included meta-analysis on the comparative clinical efficacy and safety of intranasal triamcinolone and beclomethasone dipropionate in the treatment of allergic rhinitis showed that both drugs had similar efficacy in reducing nasal and ocular symptoms, but intranasal triamcinolone is safer than beclomethasone in terms of risk of epistaxis, long-term effects on growth, and systemic ocular effects.
Subject indexing assigned by CRD
Administration, Intranasal; Beclomethasone; Rhinitis; Triamcinolone Acetonides
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published